

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer
Pursuant to Rule 13a - 16 under
the Securities Exchange Act of 1934

For the period ended August 4, 2005

ICON plc
(Registrant's name)

0-29714
(Commission file number)

South County Business Park, Leopardstown, Dublin 18, Ireland.
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Yes No

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes No

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes No

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82 N/A

Other Events.

The registrant hereby incorporates by reference the press release attached hereto as Exhibit 99.1 into this report.

Financial Statements and Exhibits.

(c) The following Exhibits are filed as part of this report:

EXHIBIT NO. -----	DESCRIPTION -----
99.1	Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ICON plc

August 4, 2005

Date

/s/ Sean Leech

Sean Leech
Chief Financial Officer

ICON reports 10% increase in net revenues and EPS of 42 cents. (NASDAQ:ICLR)

Highlights - Fourth Quarter and Full Year Fiscal 2005

- * Fourth quarter net revenues increased 10% over the fourth quarter of fiscal 2004 to \$86.0 million and also increased 10% on a full year basis.
- * Income from operations decreased 24% over the fourth quarter of fiscal 2004 to \$7.4 million and decreased 13% on a full year basis, excluding the impact of one-time charges taken in the third quarter.
- * Diluted earnings per share decreased by 18% for the fourth quarter to 42 cents compared to 51 cents in the same quarter last year. Full year pro forma diluted earnings per share was \$1.70 compared to \$1.88 for the comparable period last year.
- * \$101 million of net new business awarded to ICON during the quarter.

Dublin, Ireland, August 2, 2005 - ICON plc (NASDAQ: ICLR), a global contract clinical research organisation, which has approximately 2,700 employees providing services to the pharmaceutical, biotech and medical device industries from 37 locations in 23 countries worldwide, today reported the financial results for its fourth quarter and full year ended May 31, 2005.

Net revenues for the quarter were \$86.0 million, representing an 10% increase over net revenues of \$77.9 million for the same quarter last year. Excluding the impact of acquisitions, revenue growth for the quarter was 8% over the same quarter last year.

Income from operations was \$7.4 million, which represents a decrease of 24% from the \$9.6 million reported for the fourth quarter last year. Operating margin for the quarter was 8.6% compared to 12.4% for the equivalent period last year. Net income for the quarter was \$5.9 million or 42 cents per share, on a diluted basis, compared with \$7.2 million or 51 cents per share for the fourth quarter last year.

In the twelve months to May 31, 2005, net revenues were \$326.7 million, representing a 10% increase over net revenues of \$296.9 million reported for the twelve months of last year. Excluding the impact of acquisitions, revenue growth was 7% for the twelve months ending May 31, 2005.

Pro forma income from operations for fiscal 2005, excluding the impact of the one-time charges announced last quarter, was \$29.9 million, representing a decrease of 13% from the \$34.4 million reported for the same period last year. Pro forma operating margin for the twelve months to May 31, 2005 was 9.1%, compared to 11.6% for the comparative period. Pro forma net income was \$24.1 million or \$1.70 per share, on a diluted basis, compared with \$25.7 million or \$1.88 per share reported for the same period last year.

Days sales outstanding, comprising accounts receivable and unbilled revenue less payments on account, were 63 days at May 31, 2005 compared to 67 days at February 28, 2005 and 60 days at May 31, 2004.

For the quarter ended May 31, 2005, cash generated from operations was \$13.2 million, and capital expenditure was \$5.3 million. For the twelve months to May 31, 2005, cash generated from operations was \$23.8 million, capital expenditure was \$15.6 million and net payments of \$9.8 million were made in relation to acquisitions. As a result of these factors the company's net cash, short-term debt and short-term investments were \$78.4 million at May 31, 2005, compared to \$70.9 million at February 28, 2005 and \$78.8 million at May 31, 2004.

The company also announced that it intends to change its year end date from May 31 to December 31. Accordingly, the current accounting period for the company will end on December 31, 2005. The change has been implemented in order to align the company's year end more conveniently with the calendar year for reporting purposes. "The results for the quarter were in line with our expectations and represented a good improvement over the previous quarter", commented Chairman, Dr John Climax. "We had solid net new business awards of \$101 million in the quarter and we completed fiscal 2005 with a total backlog of over \$525 million".

Commenting on the outlook, Dr Climax said "We expect growth in all divisions as the year progresses and we expect our lab business to return to profitability during the first half of calendar 2006. With approximately \$262 million of backlog which will be earned in the next twelve months, we expect overall net revenues for the coming four quarters to be in the \$370 - \$380 million range. We will provide more detailed guidance on our conference call to be held today".

The company will hold its fourth quarter conference call today, August 2nd, 2005

at 08:00 EST [13:00 BST / 14:00 CET]. This call and linked slide presentation can be accessed live from our website at <http://www.iconclinical.com>. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under "shareholders services". This calendar will be updated regularly.

The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. In addition to the matters described in this press release, the ability to maintain large client contracts or enter into new contracts, maintain client relationships and the ability to manage the opening of new offices, the integration of new business mergers and acquisitions, as well as other risks and uncertainties detailed from time to time in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, may affect the actual results achieved by ICON. ICON disclaims any intent or obligation to update these forward-looking statements.

The financial information presented herein has been prepared in accordance with U.S. GAAP.

Source: ICON plc

Contact : Investor Relations 1-888-381-7923 or Sean Leech CFO + 353 -1-291-2000
Both at ICON.

<http://www.iconclinical.com>

ICON plc

Consolidated Income Statements
(Audited)

Three and Twelve Months ended May 31, 2005 and May 31, 2004
(Dollars, in thousands, except share and per share data)

	Three Months Ended		Twelve Months Ended	
	May 31, 2005	May 31, 2004	May 31, 2005	May 31, 2004
Gross Revenue	121,979	111,694	469,583	443,875
Subcontractor costs	36,010	33,775	142,925	146,952
Net Revenue	85,969	77,919	326,658	296,923
Costs and expenses				
Direct costs	47,529	42,291	179,661	162,562
Selling, general and administrative	27,540	23,033	103,784	88,807
Depreciation and amortization	3,549	2,956	13,331	11,171
One-time charges	-	-	11,275	-
Total costs and expenses	78,618	68,280	308,051	262,540
Income from operations	7,351	9,639	18,607	34,383
Interest income (net)	381	91	979	288
Income before provision of income taxes	7,732	9,730	19,586	34,671
Provision for income taxes	1,699	2,508	5,852	8,929
Minority Interest	84	-	189	-
Net income	5,949	7,222	13,545	25,742
Net income per ordinary share				
Basic	\$0.43	\$0.53	\$0.98	\$1.94
Diluted	\$0.42	\$0.51	\$0.96	\$1.88
Weighted average number of ordinary shares				
Basic	13,887,989	13,714,899	13,860,203	13,267,531
Diluted	14,100,098	14,080,617	14,153,445	13,703,163

ICON plc

Proforma Consolidated Income Statements *
(Unaudited)

Three and Twelve Months ended May 31, 2005 and May 31, 2004
(Dollars, in thousands, except share and per share data)

	Three Months Ended		Twelve Months Ended	
	May 31, 2005	May 31, 2004	May 31, 2005	May 31, 2004
Gross Revenue	121,979	111,694	469,583	443,875
Subcontractor costs	36,010	33,775	142,925	146,952
Net Revenue	85,969	77,919	326,658	296,923
Costs and expenses				
Direct costs	47,529	42,291	179,661	162,562
Selling, general and administrative	27,540	23,033	103,784	88,807
Depreciation and amortization	3,549	2,956	13,331	11,171
Total costs and expenses	78,618	68,280	296,776	262,540
Income from operations	7,351	9,639	29,882	34,383
Interest income (net)	381	91	979	288
Income before provision of income taxes	7,732	9,730	30,861	34,671
Provision for income taxes	1,699	2,508	6,577	8,929
Minority Interest	84	-	189	-
Net income *	5,949	7,222	24,095	25,742
Net income per ordinary share				
Basic *	\$0.43	\$0.53	\$1.74	\$1.94
Diluted *	\$0.42	\$0.51	\$1.70	\$1.88
Weighted average number of ordinary shares				
Basic	13,887,989	13,714,899	13,860,203	13,267,531
Diluted	14,100,098	14,080,617	14,153,445	13,703,163

* Excludes a one-time charge of \$10.6 million relating to the recognition of an impairment of the goodwill associated with the Central Laboratory business, certain assets, lease termination costs and exit costs, net of the tax deduction thereon.

ICON plc

Summary Balance Sheet Data
May 31, 2005 and May 31, 2004
(Dollars, in thousands)

	May 31, 2005 (audited)	May 31, 2004
(audited)		
Cash and short-term investments	78,375	78,763
Short-term debt	-	-
Net cash	78,375	78,763
Accounts receivable	83,909	74,079
Unbilled revenue	86,098	59,861
Payments on account	(85,342)	(61,960)
Total	84,665	71,980
Working Capital	125,288	113,813
Total assets	380,312	335,323
Shareholders' equity	233,066	216,760

Source: ICON plc

Contact: Investor Relations 1-888-381-7923 or
Sean Leech CFO + 353 1 291 2000
both at ICON.

<http://www.iconclinical.com>